Objective: To explore the effect of thrombolysis with anticoagulation treatment for early stage of deep vein thrombosis of lower extremity. Methods: The clinical data of 106 patients at the early stage of deep vein th...Objective: To explore the effect of thrombolysis with anticoagulation treatment for early stage of deep vein thrombosis of lower extremity. Methods: The clinical data of 106 patients at the early stage of deep vein thrombosis (DVT) in the lower extremities treated by thrombolysis with anticoagulation and dispersion drugs were analyzed retrospectively. Results: The thrombolytic effect was significant. After treatment, the deep veins were recanalized without regurgitation in 75.3% of the patients. The total effective rate was 100%. Only three patients had hemorrhagic complication, but none of the patients died. Conclusion: Thrombolysis with anticoagulation treatment is an effective and safe method for DVT at the early stage.展开更多
A synthetic diblock copolymer poly（2-ethyl-2-oxazoline）-poly（D,L-lactide） （PEOz-PLA） can self-assemble into micelles with an increased efficiency of drug delivery. However, the interactions of blood-micelles and...A synthetic diblock copolymer poly（2-ethyl-2-oxazoline）-poly（D,L-lactide） （PEOz-PLA） can self-assemble into micelles with an increased efficiency of drug delivery. However, the interactions of blood-micelles and cell-micelles remain unclear. In the present study, we aimed to assess the hemocompatibility and cytocompatibility of PEOz-PLA micelles in order to clarify its potentials as carriers for drug delivery. Blood compatibility of the micelles was evaluated by hemolysis analysis, coagulation test, platelet activation investigation and assessment of their interaction with protein. The results revealed that PEOz-PLA micelles had a favorable blood compatibility. In addition, PEOz-PLA micelles showed a good cytocompatibility through SRB assay, presenting only negligible cytotoxicity when incubated with KBv cells. Taken together, PEOz-PLA micelles could be used as a hemocompatible and cytocompatible drug carrier for intravenous administration.展开更多
文摘Objective: To explore the effect of thrombolysis with anticoagulation treatment for early stage of deep vein thrombosis of lower extremity. Methods: The clinical data of 106 patients at the early stage of deep vein thrombosis (DVT) in the lower extremities treated by thrombolysis with anticoagulation and dispersion drugs were analyzed retrospectively. Results: The thrombolytic effect was significant. After treatment, the deep veins were recanalized without regurgitation in 75.3% of the patients. The total effective rate was 100%. Only three patients had hemorrhagic complication, but none of the patients died. Conclusion: Thrombolysis with anticoagulation treatment is an effective and safe method for DVT at the early stage.
基金National Natural Science Foundation of China(Grant No.81172990)the National Key Science Research Program of China(Grant No.973 Program,2009CB930300)+1 种基金Innovation Team of Ministry of Education(Grant No.BMU20110263)the Open Project Program of State Key Laboratory of Drug Delivery Technology and Pharmacokinetics,Tianjin Institute of Pharmaceutical Research
文摘A synthetic diblock copolymer poly（2-ethyl-2-oxazoline）-poly（D,L-lactide） （PEOz-PLA） can self-assemble into micelles with an increased efficiency of drug delivery. However, the interactions of blood-micelles and cell-micelles remain unclear. In the present study, we aimed to assess the hemocompatibility and cytocompatibility of PEOz-PLA micelles in order to clarify its potentials as carriers for drug delivery. Blood compatibility of the micelles was evaluated by hemolysis analysis, coagulation test, platelet activation investigation and assessment of their interaction with protein. The results revealed that PEOz-PLA micelles had a favorable blood compatibility. In addition, PEOz-PLA micelles showed a good cytocompatibility through SRB assay, presenting only negligible cytotoxicity when incubated with KBv cells. Taken together, PEOz-PLA micelles could be used as a hemocompatible and cytocompatible drug carrier for intravenous administration.
